Thanh Quang Nguyen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Thanh Quang Nguyen has a total of 90 co-authors. Here are the top co-authors by number of shared publications:
- Jichan Jang
Division of Life Science, Department of Bio & Medical Big Data (BK21 Four Program), Research Institute of Life Science, Gyeongsang National University, Jinju 52828, Republic of Korea
10 shared publications Bo Eun Heo
Division of Life Science Department of Bio & Medical Big Data (BK21 Four Program) Research Institute of Life Science Gyeongsang National University 52828 Jinju Republic of Korea
8 shared publicationsSeunghyeon Jeon
Division of Life Science, Department of Bio & Medical Big Data (BK21 Four Program), Research Institute of Life Science, Gyeongsang National University, Jinju, Republic of Korea
5 shared publicationsBui Thi Bich Hanh
Division of Applied Life Science (BK21 Four Program), Research Institute of Life Science, Gyeongsang National University, Jinju, Republic of Korea
4 shared publicationsCheol Moon
Department of Clinical Laboratory Science, Semyung University, Jecheon, Republic of Korea
4 shared publications- Dong-Chan Oh
Seoul National University
4 shared publications
Latest Publications
- 20 April 2026
- Published by American Chemical Society (ACS) in ACS Infectious Diseases
- Vol. 12 (5) , 1496-1515
Mycobacterium avium : Diversity, Clinical Significance, Old and New Targeted Medicines
The Mycobacterium avium complex (MAC) comprises opportunistic pathogens of growing clinical significance, particularly in immunocompromised individuals and aging populations. Advances in molecular genomics have refined MAC taxonomy, enabling more precise diagnosis and informing therapeutic strategies. Whole-genome sequencing has revealed substantial genomic diversity within MAC, particularly in M. avium subsp. hominissuis (MAH), the predominant subspecies isolated from patients, and has helped identifying genetic determinants of strain-specific adaptation, virulence, and environmental persistence. The escalating incidence of MAH infections represents a pressing public health concern, further complicated by intrinsic and acquired antimicrobial resistance and the absence of standardized susceptibility testing. This review integrates recent developments in MAC taxonomy and epidemiology, with a particular focus on MAH pathogenesis, and provides an updated overview of the drug discovery landscape. We highlight innovative strategies, including novel antimicrobials and host-directed therapies, with the goal of developing safer, more effective medication. By linking mechanistic insights to translational applications, this work underscores the potential to improve clinical outcomes in patients affected by MAH infections and provides a framework for future precision-guided therapies.
- 20 April 2026
- Published by American Chemical Society (ACS) in ACS Infectious Diseases
- Vol. 12 (5) , 1496-1515
Mycobacterium avium : Diversity, Clinical Significance, Old and New Targeted Medicines
The Mycobacterium avium complex (MAC) comprises opportunistic pathogens of growing clinical significance, particularly in immunocompromised individuals and aging populations. Advances in molecular genomics have refined MAC taxonomy, enabling more precise diagnosis and informing therapeutic strategies. Whole-genome sequencing has revealed substantial genomic diversity within MAC, particularly in M. avium subsp. hominissuis (MAH), the predominant subspecies isolated from patients, and has helped identifying genetic determinants of strain-specific adaptation, virulence, and environmental persistence. The escalating incidence of MAH infections represents a pressing public health concern, further complicated by intrinsic and acquired antimicrobial resistance and the absence of standardized susceptibility testing. This review integrates recent developments in MAC taxonomy and epidemiology, with a particular focus on MAH pathogenesis, and provides an updated overview of the drug discovery landscape. We highlight innovative strategies, including novel antimicrobials and host-directed therapies, with the goal of developing safer, more effective medication. By linking mechanistic insights to translational applications, this work underscores the potential to improve clinical outcomes in patients affected by MAH infections and provides a framework for future precision-guided therapies.
- Open Access
- 8 April 2026
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 302 (6) , 111433
Pharmacological targeting of the mycothiol cysteine ligase MshC in Mycobacterium abscessus
- 8 April 2026
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 302 (6) , 111433
Open AccessPharmacological targeting of the mycothiol cysteine ligase MshC in Mycobacterium abscessus
- Open Access
- 13 November 2024
- Published by Wiley in Angewandte Chemie International Edition
- Vol. 64 (1) , e202412994
Arenicolide Family Macrolides Provide a New Therapeutic Lead Combating Multidrug‐Resistant Tuberculosis
The emergence of multidrug‐resistant (MDR) and extensively drug‐resistant (XDR) strains of Mycobacterium tuberculosis (Mtb) poses a significant threat to health globally. During searching for new chemical entities regulating MDR‐ and XDR‐Mtb, chemical investigation of the black oil beetle gut bacterium Micromonospora sp. GR10 led to the discovery of eight new members of arenicolides along with the identification of arenicolide A (Ar−A, 1), which was a previously reported macrolide with incomplete configuration. Genomic analysis of the bacterial strain GR10 revealed their putative biosynthetic pathway. Quantum mechanics‐based computation, chemical derivatizations, and bioinformatic analysis established the absolute stereochemistry of Ar−A and arenicolides D−K (Ar−D−K, 2–9) completely for the first time. Biological studies of 1–9 revealed their antimicrobial activity against MDR and XDR strains of Mtb. Ar−A had the most potent in vitro antimicrobial efficacy against MDR‐ and XDR‐Mtb. Mechanistically, Ar−A induced ATP depletion and destabilized Mtb cell wall, thereby inhibiting growth. Notably, Ar−A exerted a significant antimicrobial effect against Mtb in macrophages, was effective in the treatment of Mtb infections, and showed a synergistic effect with amikacin (AMK) in a mouse model of MDR‐Mtb lung infection. Collectively, our findings indicate Ar−A to be a promising drug lead for drug‐resistant tuberculosis.
- 13 November 2024
- Published by Wiley in Angewandte Chemie International Edition
- Vol. 64 (1) , e202412994
Open AccessArenicolide Family Macrolides Provide a New Therapeutic Lead Combating Multidrug‐Resistant Tuberculosis
The emergence of multidrug‐resistant (MDR) and extensively drug‐resistant (XDR) strains of Mycobacterium tuberculosis (Mtb) poses a significant threat to health globally. During searching for new chemical entities regulating MDR‐ and XDR‐Mtb, chemical investigation of the black oil beetle gut bacterium Micromonospora sp. GR10 led to the discovery of eight new members of arenicolides along with the identification of arenicolide A (Ar−A, 1), which was a previously reported macrolide with incomplete configuration. Genomic analysis of the bacterial strain GR10 revealed their putative biosynthetic pathway. Quantum mechanics‐based computation, chemical derivatizations, and bioinformatic analysis established the absolute stereochemistry of Ar−A and arenicolides D−K (Ar−D−K, 2–9) completely for the first time. Biological studies of 1–9 revealed their antimicrobial activity against MDR and XDR strains of Mtb. Ar−A had the most potent in vitro antimicrobial efficacy against MDR‐ and XDR‐Mtb. Mechanistically, Ar−A induced ATP depletion and destabilized Mtb cell wall, thereby inhibiting growth. Notably, Ar−A exerted a significant antimicrobial effect against Mtb in macrophages, was effective in the treatment of Mtb infections, and showed a synergistic effect with amikacin (AMK) in a mouse model of MDR‐Mtb lung infection. Collectively, our findings indicate Ar−A to be a promising drug lead for drug‐resistant tuberculosis.
- Open Access
- 20 August 2024
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 179, 117313
The autophagy-targeting compound V46 enhances antimicrobial responses to Mycobacteroides abscessus by activating transcription factor EB
- 20 August 2024
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 179, 117313
Open AccessThe autophagy-targeting compound V46 enhances antimicrobial responses to Mycobacteroides abscessus by activating transcription factor EB
- 5 March 2024
- Published by American Chemical Society (ACS) in Journal of Natural Products
- Vol. 87 (3) , 591-599
Retinestatin, a Polyol Polyketide from a Termite Nest-Derived Streptomyces sp.
A new polyol polyketide, named retinestatin (1), was obtained and characterized from the culture of a Streptomyces strain, which was isolated from a subterranean nest of the termite Reticulitermes speratus kyushuensis Morimoto. The planar structure of 1 was elucidated on the basis of the cumulative analysis of ultraviolet, infrared, mass spectrometry, and nuclear magnetic resonance spectroscopic data. The absolute configuration of 1 at 12 chiral centers was successfully assigned by employing a J-based configuration analysis in combination with ROESY correlations, a quantum mechanics-based computational approach to calculate NMR chemical shifts, and a 3 min flash esterification by Mosher's reagents followed by NMR analysis. Biological evaluation of retinestatin (1) using an in vitro model of Parkinson's disease revealed that 1 protected SH-SY5Y dopaminergic cells from MPP+-induced cytotoxicity, indicating its neuroprotective effects.
- 5 March 2024
- Published by American Chemical Society (ACS) in Journal of Natural Products
- Vol. 87 (3) , 591-599
Retinestatin, a Polyol Polyketide from a Termite Nest-Derived Streptomyces sp.
A new polyol polyketide, named retinestatin (1), was obtained and characterized from the culture of a Streptomyces strain, which was isolated from a subterranean nest of the termite Reticulitermes speratus kyushuensis Morimoto. The planar structure of 1 was elucidated on the basis of the cumulative analysis of ultraviolet, infrared, mass spectrometry, and nuclear magnetic resonance spectroscopic data. The absolute configuration of 1 at 12 chiral centers was successfully assigned by employing a J-based configuration analysis in combination with ROESY correlations, a quantum mechanics-based computational approach to calculate NMR chemical shifts, and a 3 min flash esterification by Mosher's reagents followed by NMR analysis. Biological evaluation of retinestatin (1) using an in vitro model of Parkinson's disease revealed that 1 protected SH-SY5Y dopaminergic cells from MPP+-induced cytotoxicity, indicating its neuroprotective effects.
- Top Cited PapersOpen Access
- 6 February 2024
- Published by Frontiers Media SA in Frontiers in Microbiology
- Vol. 15, 1331508
Exploring antibiotic resistance mechanisms in Mycobacterium abscessus for enhanced therapeutic approaches
Mycobacterium abscessus, a leading cause of severe lung infections in immunocompromised individuals, poses significant challenges for current therapeutic strategies due to resistance mechanisms. Therefore, understanding the intrinsic and acquired antibiotic resistance of M. abscessus is crucial for effective treatment. This review highlights the mechanisms employed by M. abscessus to sustain antibiotic resistance, encompassing not only conventional drugs but also newly discovered drug candidates. This comprehensive analysis aims to identify novel entities capable of overcoming the notorious resistance exhibited by M. abscessus, providing insights for the development of more effective therapeutic interventions.
- 6 February 2024
- Published by Frontiers Media SA in Frontiers in Microbiology
- Vol. 15, 1331508
Top Cited PapersOpen AccessExploring antibiotic resistance mechanisms in Mycobacterium abscessus for enhanced therapeutic approaches
Mycobacterium abscessus, a leading cause of severe lung infections in immunocompromised individuals, poses significant challenges for current therapeutic strategies due to resistance mechanisms. Therefore, understanding the intrinsic and acquired antibiotic resistance of M. abscessus is crucial for effective treatment. This review highlights the mechanisms employed by M. abscessus to sustain antibiotic resistance, encompassing not only conventional drugs but also newly discovered drug candidates. This comprehensive analysis aims to identify novel entities capable of overcoming the notorious resistance exhibited by M. abscessus, providing insights for the development of more effective therapeutic interventions.
- 15 June 2023
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 67 (6) , e0156722
DS86760016, a Leucyl-tRNA Synthetase Inhibitor, Is Active against Mycobacterium abscessus
Benzoxaboroles are a new class of leucyl-tRNA synthetase inhibitors. Epetraborole, a benzoxaborole, is a clinical candidate developed for Gram-negative infections and has been confirmed to exhibit favorable activity against a well known pulmonary pathogen, Mycobacterium abscessus .
- 15 June 2023
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 67 (6) , e0156722
DS86760016, a Leucyl-tRNA Synthetase Inhibitor, Is Active against Mycobacterium abscessus
Benzoxaboroles are a new class of leucyl-tRNA synthetase inhibitors. Epetraborole, a benzoxaborole, is a clinical candidate developed for Gram-negative infections and has been confirmed to exhibit favorable activity against a well known pulmonary pathogen, Mycobacterium abscessus .
- Open Access
- 15 June 2023
- Published by American Society for Microbiology in Microbiology Spectrum
- Vol. 11 (3) , e0063123
CRISPR Interference-Based Inhibition of MAB_0055c Expression Alters Drug Sensitivity in Mycobacterium abscessus
In this study, we utilized CRISPR interference (CRISPRi) to specifically target the MAB_0055c gene in M. abscessus , a bacterium that causes difficult-to-treat infections. The study found that silencing the gene lead to increased rifabutin and rifalazil susceptibility.
- 15 June 2023
- Published by American Society for Microbiology in Microbiology Spectrum
- Vol. 11 (3) , e0063123
Open AccessCRISPR Interference-Based Inhibition of MAB_0055c Expression Alters Drug Sensitivity in Mycobacterium abscessus
In this study, we utilized CRISPR interference (CRISPRi) to specifically target the MAB_0055c gene in M. abscessus , a bacterium that causes difficult-to-treat infections. The study found that silencing the gene lead to increased rifabutin and rifalazil susceptibility.
- 20 December 2022
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 66 (12) , e0044822
Synergistic Effect of Q203 Combined with PBTZ169 against Mycobacterium tuberculosis
Q203 is a first-in-class drug candidate against Mycobacterium tuberculosis . In its recently completed phase 2 clinical trial, Q203 reduced the number of live M. tuberculosis cells in a dose-dependent manner.
- 20 December 2022
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 66 (12) , e0044822
Synergistic Effect of Q203 Combined with PBTZ169 against Mycobacterium tuberculosis
Q203 is a first-in-class drug candidate against Mycobacterium tuberculosis . In its recently completed phase 2 clinical trial, Q203 reduced the number of live M. tuberculosis cells in a dose-dependent manner.
- Open Access
- 15 November 2022
- Published by Taylor & Francis in Virulence
- Vol. 13 (1) , 1966-1984
Ohmyungsamycin promotes M1-like inflammatory responses to enhance host defence against Mycobacteroides abscessus infections
Ohmyungsamycin A (OMS) is a newly identified cyclic peptide that exerts antimicrobial effects against Mycobacterium tuberculosis. However, its role in nontuberculous mycobacteria (NTMs) infections has not been clarified. Mycobacteroides abscessus (Mabc) is a rapidly growing NTM that has emerged as a human pathogen in both immunocompetent and immunosuppressed individuals. In this study, we demonstrated that OMS had significant antimicrobial effects against Mabc infection in both immunocompetent and immunodeficient mice, and in macrophages. OMS treatment amplified Mabc-induced expression of M1-related proinflammatory cytokines and inducible nitric oxide synthase, and significantly downregulated arginase-1 expression in murine macrophages. In addition, OMS augmented Mabc-mediated production of mitochondrial reactive oxygen species (mtROS), which promoted M1-like proinflammatory responses in Mabc-infected macrophages. OMS-induced production of mtROS and nitric oxide was critical for OMS-mediated antimicrobial responses during Mabc infections. Notably, the combination of OMS and rifabutin had a synergistic effect on the antimicrobial responses against Mabc infections in vitro, in murine macrophages, and in zebrafish models in vivo. Collectively, these data strongly suggest that OMS may be an effective M1-like adjunctive therapeutic against Mabc infections, either alone or in combination with antibiotics.
- 15 November 2022
- Published by Taylor & Francis in Virulence
- Vol. 13 (1) , 1966-1984
Open AccessOhmyungsamycin promotes M1-like inflammatory responses to enhance host defence against Mycobacteroides abscessus infections
Ohmyungsamycin A (OMS) is a newly identified cyclic peptide that exerts antimicrobial effects against Mycobacterium tuberculosis. However, its role in nontuberculous mycobacteria (NTMs) infections has not been clarified. Mycobacteroides abscessus (Mabc) is a rapidly growing NTM that has emerged as a human pathogen in both immunocompetent and immunosuppressed individuals. In this study, we demonstrated that OMS had significant antimicrobial effects against Mabc infection in both immunocompetent and immunodeficient mice, and in macrophages. OMS treatment amplified Mabc-induced expression of M1-related proinflammatory cytokines and inducible nitric oxide synthase, and significantly downregulated arginase-1 expression in murine macrophages. In addition, OMS augmented Mabc-mediated production of mitochondrial reactive oxygen species (mtROS), which promoted M1-like proinflammatory responses in Mabc-infected macrophages. OMS-induced production of mtROS and nitric oxide was critical for OMS-mediated antimicrobial responses during Mabc infections. Notably, the combination of OMS and rifabutin had a synergistic effect on the antimicrobial responses against Mabc infections in vitro, in murine macrophages, and in zebrafish models in vivo. Collectively, these data strongly suggest that OMS may be an effective M1-like adjunctive therapeutic against Mabc infections, either alone or in combination with antibiotics.